Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
Terminated
Solvay Pharmaceuticals
Phase 4
2006-08-01
This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment
of children and adolescents with obsessive-compulsive disorder
Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents
Completed
Solvay Pharmaceuticals
Phase 4
2006-10-01
This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the
treatment of children and adolescents with depression or depressive state
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Completed
Meiji Seika Pharma Co., Ltd.
Phase 3
2013-08-14
The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine
compared to placebo on change in total score of Japanese version of the Children's Yale-Brown
Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10
weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD).
The objective of the second phase of the study is to evaluate the long-term safety and
efficacy of fluvoxamine in pediatric/adolescent patients with OCD.
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Completed
AbbVie
Phase 3
2013-08-14
The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine
compared to placebo on change in total score of Japanese version of the Children's Yale-Brown
Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10
weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD).
The objective of the second phase of the study is to evaluate the long-term safety and
efficacy of fluvoxamine in pediatric/adolescent patients with OCD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
